1. Home
  2. MATV vs PSNL Comparison

MATV vs PSNL Comparison

Compare MATV & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mativ Holdings Inc.

MATV

Mativ Holdings Inc.

HOLD

Current Price

$14.69

Market Cap

701.0M

ML Signal

HOLD

Logo Personalis Inc.

PSNL

Personalis Inc.

HOLD

Current Price

$8.16

Market Cap

746.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MATV
PSNL
Founded
1995
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Paper
Medical Specialities
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
701.0M
746.8M
IPO Year
1995
2019

Fundamental Metrics

Financial Performance
Metric
MATV
PSNL
Price
$14.69
$8.16
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
6
Target Price
$10.00
$11.17
AVG Volume (30 Days)
272.7K
1.4M
Earning Date
02-18-2026
02-26-2026
Dividend Yield
2.75%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,982,500,000.00
$69,103,000.00
Revenue This Year
$2.62
N/A
Revenue Next Year
$2.26
$19.41
P/E Ratio
N/A
N/A
Revenue Growth
0.39
N/A
52 Week Low
$4.34
$2.83
52 Week High
$14.95
$11.50

Technical Indicators

Market Signals
Indicator
MATV
PSNL
Relative Strength Index (RSI) 65.96 37.39
Support Level $11.76 $7.27
Resistance Level $14.29 $9.79
Average True Range (ATR) 0.49 0.86
MACD 0.14 -0.30
Stochastic Oscillator 87.36 8.51

Price Performance

Historical Comparison
MATV
PSNL

About MATV Mativ Holdings Inc.

Mativ Holdings Inc is a leader in specialty materials, solving its customers' complex challenges by engineering bold, inventive solutions that connect, protect, and purify the world. The company operates in two segments namely Filtration & advanced Materials focused on filtration media and components, developed films, coating and converting solutions, and extruded mesh products, and (2) Sustainable & Adhesive Solutions (SAS), focused on tapes, labels, liners, specialty paper, packaging and healthcare solutions.

About PSNL Personalis Inc.

Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.

Share on Social Networks: